Lornoxicam more effective than rofecoxib for active osteoarthritis

By  

Inpharma, Vol. 1, Iss. 1435, 2004-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis

By Schmidt H.   Woodcock B.G.   Geisslinger G.  

Drug Safety, Vol. 27, Iss. 3, 2004-01 ,pp. : 185-196

Adis International

Access to resources Recommend Favorite

Direct-to-consumer (DTC) advertising of rofecoxib [Vioxx] and celecoxib [Celebrex] increased the number of patients with osteoarthritis (OA) seen by physicians each month

By  

Inpharma, Vol. 1, Iss. 1571, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Direct-to-consumer (DTC) advertising of rofecoxib [Vioxx] and celecoxib [Celebrex] increased the number of patients with osteoarthritis (OA) seen by physicians each month

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 519, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Safety of Lornoxicam in the Treatment of Postoperative Pain: A Post-Marketing Study of Analgesic Regimens Containing Lornoxicam Compared with Standard Analgesic Treatment in 3752 Day-Case Surgery Patients

By Rawal Narinder  

Clinical Drug Investigation, Vol. 30, Iss. 10, 2010-10 ,pp. : 687-697

Adis International

Access to resources Recommend Favorite